Kidney Cancer

What You Need to Know About Kidney Cancer

Nurse navigator Cheryl Bellomo offers vital information on kidney cancer including genetic factors, symptoms, and treatment options.
June 2015 Vol 1 No 3
Cheryl Bellomo, MSN, RN, OCN, HON-ONN-CG
Oncology Nurse Navigator
Intermountain-Southwest Cancer Center
Cedar City Hospital
Cedar City, UT

Kidney cancer (also called renal cancer) is among the 10 most common cancers in men and in women. The American Cancer Society estimates that in 2015, 61,560 new cases of kidney cancer, 38,270 in men and 23,290 in women, will be diagnosed, and 14,080 patients will die from this disease in the United States. The lifetime risk for kidney cancer is about 1 in 63 (1.6%); the risk is higher in men than in women.

Risk Factors

Certain factors can increase the risk for kidney cancer. Perhaps the biggest risk factor is increasing age: being older than age 40 puts an individual at greater risk for kidney cancer. Certain lifestyle behaviors and medical conditions are also believed to increase the risk for kidney cancer. These include:

  • Cigarette smoking
  • Obesity
  • Exposure to environmental substances, such as asbestos, cadmium, benzene, and herbicides
  • High blood pressure
  • Kidney disease and long-term dialysis

People with a strong family history of kidney cancer, especially siblings, are at higher risk for this cancer. African Americans and American Indians/Alaska Natives have slightly higher rates of kidney cancer than Caucasians.

Genetic Factors

There are genetic syndromes that run in families, such as defects (mutations) in the VHL, MET, FH, FLCN, SDHB, and SDHD genes, that increase the risk for kidney cancer. Defects in the SDHB and SDHD genes can cause Cowden-like syndrome, which puts people at greater risk for breast, thyroid, and kidney cancers.

Therefore, it is important to let your physician know if anyone else in your family has been diagnosed with cancer.


Early kidney cancers do not usually cause any symptoms, but as the tumors grow larger, symptoms may appear. Possible signs and symptoms of kidney cancer include blood in the urine (hematuria); a lump or mass on the side or lower back; lower back pain on one side, not related to an injury; fatigue; weight loss; anemia; and swelling of the ankles or legs.

Types of Kidney Cancer

Renal-cell carcinoma (cancer in the lining of the tubules of the kidney) is the most common type of kidney cancer. Approximately 9 in 10 kidney cancers are renal-cell carcinoma. Renal-cell carcinoma is divided into several subtypes, including clear cell renal-cell carcinoma; papillary renal-cell carcinoma; and chromophobe renal-cell carcinoma.

Other types of kidney cancers include transitional-cell carcinoma (urothelial), Wilms tumor, and renal sarcoma.


At this time, there is no screening used in the general population to reduce the risk for kidney cancer. The diagnosis of kidney cancer is made with a physical exam; health history; laboratory tests, including blood work and urinalysis; and imaging tests, including ultrasound, intravenous pyelogram, CT scan, MRI, and renal arteriogram.


Once a diagnosis is confirmed and the staging is complete, surgeons and oncologists can initiate the treatment plan. The types of treatment for kidney cancer include surgical removal of the kidney (nephrectomy), cryotherapy and radiofrequency ablation, radiation therapy, chemotherapy, and targeted therapy.

Surgery is the main treatment for most kidney cancers.

Because the kidneys are not very sensitive to radiation, radiation therapy is generally used for patients who cannot tolerate surgery or for palliative control of symptoms related to the spread of cancer.

Targeted Therapies

As researchers have learned more about what makes kidney cancer cells different from normal cells, newer drugs have been developed that “target” the specific cancer cells. These targeted drugs block the growth of new blood vessels that nourish cancer cells (angiogenesis) or important proteins (tyrosine kinases) that help the cancer cells to grow and divide.

Targeted drugs, such as Nexavar (sorafenib), Sutent (sunitinib), and Avastin (bevacizumab), block the formation of new blood vessels in the cancer cells. Torisel (temsirolimus), Votrient (pazopanib), and Inlyta (axitinib) are targeted drugs that block tyrosine kinase proteins.

Clinical trials are being conducted to further study targeted drugs, as well as immunotherapy (drugs that use the body’s own immune system to fight cancer) for the treatment of kidney cancer.

Patient Resources

American Cancer Society

National Cancer Institute

National Kidney Foundation

Kidney Cancer Association

Share this:

Recommended For You
Kidney Cancer
Drugs for Kidney (Renal-Cell) Cancer
Here are the drugs and financial support services available to patients receiving treatment for Kidney (Renal-Cell) Cancer.
Side-Effects Management
Managing Hand & Foot Skin Reactions to Cancer Therapies
By Cheryl Bellomo, MSN, RN, OCN, HON-ONN-CG
Hand-foot skin reactions are a type of side effect associated with targeted therapies, a newer type of cancer treatment. Oncology nurse navigator Cheryl Bellomo recommends strategies to ease the pain and skin sensitivity associated with these reactions.
Kidney CancerSlideshows
March Is Kidney Cancer Awareness Month
View this slideshow to learn important facts about kidney cancer, including statistics, causes and symptoms.
FDA Approvals, News & UpdatesKidney CancerNewsworthy
Opdivo plus Yervoy First Immunotherapy Regimen for Initial Treatment of Kidney Cancer
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer.
Last modified: October 13, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.